ISCP 2025 - Day 2: Obesity, GLP-1, Cardio-Oncology & Cancer Thrombosis (S 7 & 8)

The Diet Dilemma: Dr. Tomás González opens the session by dismantling the "enemy" approach to nutrition (carbs vs. fats). Instead, he focuses on the mechanics of satiety, explaining how caloric density and stomach volume dictate hunger. He offers practical strategies for avoiding the "chemistry-changing" effects of ultra-processed foods.

The Cardiologist's Role: Prof. Luis Rodríguez Padial argues that BMI is failing to detect millions of "clinical obesity" cases. He introduces the concept of "Trapped Fat" theory and explains why perivascular and epicardial adipose tissues are not just storage depots, but active endocrine organs driving inflammation and arrhythmias directly into the myocardium.

The Pharmacological Revolution: Prof. Antoni Martínez Rubio navigates the crowded landscape of weight-loss drugs. He compares the efficacy and safety profiles of Liraglutide, Semaglutide, and Tirzepatide, while teasing the future potential of "Triple Agonists" (GLP-1, GIP, and Glucagon) that are currently in development.

Header: Cardio-Oncology: Surviving the Cure

Preventing Toxicity: Dr. Rebeca Lorca shifts the focus to preserving the heart during cancer treatment. She discusses the critical window for baseline risk assessment and the potential prophylactic use of neurohormonal blockade (ACEi, Beta-blockers) and liposomal anthracyclines to prevent left ventricular dysfunction before symptoms appear.

The Thrombosis Trap: Finally, Dr. Claudia Iglesias addresses Cancer-Associated Thrombosis, the second leading cause of death in cancer patients. She evaluates the use of risk scores like Khorana for ambulatory prophylaxis and the complex decision-making required when choosing between LMWH and DOACs in patients with thrombocytopenia or intracranial tumors.